Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
US aquaculture health and genetics company Benchmark said commercial scale trials have proved a success for its sea lice treatment Ectosan.
Zoetis is launching a new grant program for research aimed at tackling parasitic diseases and extending the efficacy of therapeutics.
US agricultural investment firm TechAccel has underlined the need for more venture capital investment in animal health – music to the ears of many start-ups in the industry.
Earlier this month, a joint webinar from Animal Pharm and Kisaco Research canvassed the opinions of three key industry experts regarding the state of innovation in animal health. Animal Pharm editor Joseph Harvey spoke to Nesya Goris of ViroVet, Theo Kanellos from Zoetis and George Gunn from Stonehaven Consulting. Below is a transcript of the webinar.
Merial is continuing to develop its portfolio for vaccines with new patent applications in October.
Amsterdam has marginally been chosen as the new location for the European Medicines Agency (EMA) and its Committee for Medicinal Products for Veterinary Use (CVMP).
Pharmaceutical company Aenova is expanding its growing animal health business with a new dedicated manufacturing site for veterinary pharmaceuticals in Latina, central Italy.
At its recent annual conference, AnimalhealthEurope gathered delegates to discuss the importance of One Health. A hot topic was the role of animal health in this landscape. Animal Pharm analyst Sian Lazell heard how the industry needs to discover innovative solutions and how this can be achieved.
Saudi Arabia's leading animal health company Montajat has launched a new range of antiparasitic products to protect livestock in the Middle East and Arabian Gulf.
Recent product approvals in Japan have seen market authorizations for Zoetis and IDEXX Laboratories.
A Canadian researcher is using genomic technology to discover a drug against parasitic roundworms in cattle.
Merck Animal Health posted a powerful 16% increase in sales during the third quarter of 2017, as Bravecto and a recent Brazilian acquisition continue to drive its performance.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.